Bimatoprost as a Treatment for Graves' Orbitopathy

ConditionGraves Ophthalmopathy

Trial statusRecruiting

Trial phaseEarly Phase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorJohns Hopkins University

About this trial

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

Bimatoprost Ophthalmic
Drug
Bimatoprost, aka Lumigan, one drop in one eye nightly

Treatment groups

3 Participants

are divided into 2 treatment groups

Group A: Bimatoprost in more proptotic eyeExperimental treatment 1 intervention

Group B: ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

Reduction in periorbital fat causing improvement in proptosis

Time frame

1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Johns Hopkins University

Lead sponsor

Source ClinicalTrials.gov

Apply now